Search

Search Constraints

You searched for: Author/Creator McLaughlin, Martin

Search Results

1. An orally bioavailable Chk1 inhibitor, CCT244747, sensitizes bladder and head and neck cancer cell lines to radiation. Issue 3 (March 2017)

5. Combination therapy with oncolytic viruses and immune checkpoint inhibitors. (2nd June 2020)

6. Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer. Issue 2 (5th August 2020)

7. Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer. Issue 2 (5th August 2020)

8. Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer. Issue 2 (5th August 2020)

9. Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer. Issue 2 (5th August 2020)

10. Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer. Issue 2 (5th August 2020)